EFPIA statement on the EU-Mexico Modernised Global Agreement and the Interim Trade Agreement
27.05.26
EFPIA welcomes the signature of the EU-Mexico Modernised Global Agreement and the Interim Trade Agreement.
Nathalie Moll, Director General, EFPIA, said:
"The Agreement is as an important step in strengthening trade relations between the European Union and Mexico, a key partner in Latin America. At a time of heightened geopolitical uncertainty and increasing pressure on international trade, this represents a meaningful opportunity to diversify EU trade flows and reinforce mutually beneficial economic partnerships."
EFPIA believes that the inclusion of commitments on Regulatory Data Protection and supplementary protection in the Intellectual Property (IP) chapter is an important step, and makes this agreement stand out compared to other trade agreements signed by the EU. To ensure that research-based pharmaceutical companies can fully benefit from these provisions, it will now be essential that the agreement enters into force without delay and that the relevant IP commitments are timely and effectively implemented by the Parties.
The agreement also introduces new market access opportunities in public procurement and commitments aimed at alignment with international regulatory standards and best practices. If properly implemented, these elements have the potential to facilitate trade in pharmaceuticals and enhance the competitiveness of the EU biopharmaceutical sector.
Nathalie Moll, Director General, EFPIA, said:
"The Agreement is as an important step in strengthening trade relations between the European Union and Mexico, a key partner in Latin America. At a time of heightened geopolitical uncertainty and increasing pressure on international trade, this represents a meaningful opportunity to diversify EU trade flows and reinforce mutually beneficial economic partnerships."
EFPIA believes that the inclusion of commitments on Regulatory Data Protection and supplementary protection in the Intellectual Property (IP) chapter is an important step, and makes this agreement stand out compared to other trade agreements signed by the EU. To ensure that research-based pharmaceutical companies can fully benefit from these provisions, it will now be essential that the agreement enters into force without delay and that the relevant IP commitments are timely and effectively implemented by the Parties.
The agreement also introduces new market access opportunities in public procurement and commitments aimed at alignment with international regulatory standards and best practices. If properly implemented, these elements have the potential to facilitate trade in pharmaceuticals and enhance the competitiveness of the EU biopharmaceutical sector.